Study on the Safety and Effects of a New Dosing Schedule for Tafasitamab with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Inclusion Criteria

• Able to provide signed consent to participate.
• Age 18 years or older.
• Confirmed diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL).
• Must provide a tumor sample for review.
• Have relapsed or refractory disease with at least one measurable tumor site.
• Have received 1 to 3 previous treatments, including one with a CD20-targeted therapy.
• Not eligible for intensive salvage therapy or stem-cell transplantation.
• Meet specific blood and organ function criteria.
• If previously treated with CD19-targeted therapy, must confirm CD19 positive lymphoma on a recent biopsy.
• Primary refractory disease with 1 to 3 previous treatments, including a CD20-targeted therapy.

Exclusion Criteria

• Currently in another clinical study or legally institutionalized.
• Have a different type of lymphoma or specific genetic markers.
• Have not stopped certain treatments or undergone major surgery recently.
• Have not recovered from previous treatment side effects.
• Previously treated with certain drugs or have allergies to study drugs.
• Recent stem cell transplantation or history of certain blood clots.
• History of other cancers that could interfere with the study.
• Positive for hepatitis B or C, or HIV.
• Have CNS lymphoma or significant health issues.
• Have certain genetic or digestive issues.
• Severe liver problems or allergies to study drugs.
• Any other condition that makes participation unsuitable.
• Women must agree to use birth control and not breastfeed or donate eggs. Men must agree to use condoms and not donate sperm.